Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.

Authors

Geoffrey J Lindeman

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Geoffrey J Lindeman , Aditya Bardia , Rebecca Bowen , Aulde Flechais , Guiyuan Lei , Alexandra Hogea , Mehrdad Mobasher , Saeed Rafii

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.

First Author: Kevin Kalinsky

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.

First Author: Severine Guiu Lahaye

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).

First Author: Alicia Frances Clare Okines

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.

First Author: Tamta Makharadze